IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single cell level, IsoPlexis\' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/11/14 | $300,000 |
Connecticut Innovations | undisclosed | |
| 09/25/17 | $13,500,000 | Series B |
Connecticut Innovations Ironwood Capital North Sound Ventures Spring Mountain Capital | undisclosed |
| 05/14/19 | $25,000,000 | Series C |
Connecticut Innovations Ironwood Capital North Sound Capital Northpond Ventures  Spring Mountain Capital | undisclosed |
| 01/09/20 | $20,000,000 | Series C |
Northpond Ventures | undisclosed |
| 01/07/21 | $135,000,000 | Series D |
Ally Bridge Group BlackRock Perceptive Advisors | undisclosed |
